The QualityStocks Daily Tuesday, November 5th, 2019

Today's Top 3 Investment Newsletters

MarketClub Analysis (NXTC) +248.92%

QualityStocks (ESSI) +201.00%

SmallCapRelations (OCLND) +58.10%

The QualityStocks Daily Stock List

Artelo Biosciences, Inc. (ARTL)

NetworkNewsWire, Simply Wall St, StockPulse, Momentous News, Market Exclusive, Stockwatch, Trading View, Proactive Investors, and Stockhouse reported previously on Artelo Biosciences, Inc. (ARTL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in La Jolla, California. It concentrates on the development of therapeutics that modulate the endocannabinoid system. The Company is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions. These include cancer, pain, and also inflammation. Established in 2011, the Company formerly went by the name Reactive Medical, Inc. It changed its corporate name to Artelo Biosciences, Inc. in April of 2017.

Artelo Biosciences’ belief is that a biopharmaceutical approach will lead to novel and high-impact therapeutics that harness the full potential of the endocannabinoid system (ECS). The endocannabinoid system (ECS) is a widespread neuromodulatory system. It plays a crucial role in human central nervous system (CNS) development, synaptic plasticity, and the response to endogenous and environmental insults.

Artelo’s business model is to develop numerous pharmacological approaches to ECS modulation. Candidate therapeutic compounds within the Company’s current portfolio are based on targeting cannabinoid receptors and endocannabinoid transport inhibition.

Artelo Biosciences pipeline encompasses many mechanisms for endocannabinoid system modulation. Specific programs now in development include ART27.13 – a high-potency GPCR Agonist (anorexia, cancer). Programs in development also include ART12.11 - proprietary cocrystal (multiple indications), and ART26.12 – a FABP5 Inhibitor (cancer, pain). Two of Artelo’s development programs were licensed from established and respected organizations. These organizations have already conducted pre-clinical research and, in some cases, clinical research.

Last week, Artelo Biosciences announced that it has selected Aptus Clinical Ltd., a specialist Clinical Contract Research Organization based in the United Kingdom (UK) with particular expertise in oncology, rare diseases and advanced therapies, as its contract research organization (CRO) for Artelo’s planned Phase 1b/2a randomized, placebo-controlled trial of ART27.13, its synthetic cannabinoid for the treatment of anorexia and weight loss associated with cancer.

This latest agreement builds on prior collaborations between Artelo and Aptus. These included feasibility studies, protocol design, as well as clinical site identification and selection. The ART27.13 program will continue to be under the operational stewardship of Artelo’s UK subsidiary at the Alderley Park BioHub in Cheshire.

Artelo Biosciences, Inc. (ARTL), closed Tuesday's trading session at $2.1651, off by 3.7733%, on 13,625 volume with 68 trades. The average volume for the last 3 months is 21,580 and the stock's 52-week low/high is $1.55309998/$12.00.

chart

Better Choice Company, Inc. (BTTR)

Street Insider, TeleTrader, Stockwatch, TradingView, Market Screener, Stockhouse, GlobeNewswire, All Cap Research, Simply Wall St, Wallet Investor, and InvestorsHub reported earlier on Better Choice Company, Inc. (BTTR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Better Choice Company, Inc. is an animal health and wellness CBD (cannabidiol) company listed on the OTC Markets’ OTCQB. It has acquired TruPet LLC and Bona Vida, Inc. Better Choice Company offers consumers a carefully curated collection of premium pet brands, hemp-derived CBD supplements, and other services that support pet wellness. Better Choice Company is headquartered in New York, New York.

The Company’s vision is to provide clean, holistic, and nutritional options for consumers who want to bring their own healthier lifestyle to their pets. Better Choice Company’s products promote wellness and support better and longer lives for pets. Its TruPet is an online seller of ultra-premium, all-natural pet food, treats and supplements. TruPet has a special focus on freeze dried and dehydrated raw products.

Bona Vida is a unique emerging CBD platform. Bona Vida’s focus is on developing a portfolio of brand and product verticals within the animal and human health and wellness space.

Better Choice’s portfolio includes TruDog, an online seller of ultra-premium, freeze-dried raw pet food, treats and supplements, and Elvis Presley’s Hound Dog, an inventive CBD platform. In addition, the portfolio includes TruGold, a hemp-based product line, and Rawgo!, a premium dehydrated dog food. Furthermore, the Company’s portfolio includes Orapup, a dental health system for dogs, TruCat, a premium pet food and supplements brand for cats, and Pet Premium, a foremost pet insurance provider.

In June 2019, Better Choice announced a strategic partnership with Authentic Brands Group (ABG). ABG (New York, New York) is a worldwide brand development, marketing and entertainment company and owner of Elvis Presley Enterprises LLC. This strategic partnership is to launch an all-new line of CBD pet products under the Elvis Presley Hound Dog brand.

In October, Better Choice Company announced the signing of a definitive agreement to acquire holistic pet foods leader Halo, Purely for Pets® (Halo®). The Halo management team will continue to manage the Halo business. Halo’s name and brands are not expected to change as a result of the transaction.

Mr. Damian Dalla-Longa, Better Choice Company Chief Executive Officer, said, “Halo® is a well-established, premium brand and falls squarely in line with our goal to build an all-encompassing, global, animal health and wellness consumer product goods company.”

Better Choice Company, Inc. (BTTR), closed Tuesday's trading session at $3.10, up 3.3333%, on 619 volume with 8 trades. The average volume for the last 3 months is 17,262 and the stock's 52-week low/high is $1.32599997/$13.2600002.

chart

Diversicare Healthcare Services, Inc. (DVCR)

Zacks, Street Insider, Stock Twits, Investing.com, MacroTrends, TMXmoney, Morningstar, Market Screener, Nasdaq, TradingView, Simply Wall St, Stockopedia, GlobeNewswire, GuruFocus, 4-Traders, Dividend.com, and Stockhouse reported previously on Diversicare Healthcare Services, Inc. (DVCR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Diversicare Healthcare Services, Inc. provides long-term care services to patients in 62 skilled nursing and senior housing centers containing 7,329 licensed nursing beds. The Company offers Short Stay Rehabilitation, Complex Medical Care, Long Term Care, Memory Care, Hospice Care, and Assisted Living. Diversicare has recognition as a first-rate provider of post-acute care and has a comprehensive team trained to administer high quality healthcare that meets patients needs. Diversicare Healthcare Services is headquartered in Brentwood, Tennessee. The Company lists on the OTC Markets’ OTCQX.

Diversicare created and provides therapy powered by Diversicare Therapy Services (DTS). The Company’s services incorporate current, evidence-based approaches to quality care and treatment in a safe environment. Diversicare Therapy Services’ (DTS’) team of talented and experienced therapists create customized rehabilitation programs based on an individual’s needs. Its physical, occupational and speech-language pathologists specialize in innovative therapeutic approaches that center on achieving an individual’s best outcomes. In many centers, DTS offers outpatient services provided by the same therapists that assisted one in getting home. DTS has a team of greater than 1,100 therapists.

Last week, Diversicare Healthcare Services announced its results for Q3 ended September 30, 2019. Net Loss from Continuing Operations was $1.9 million, or $0.30 per share, versus a Net Loss from Continuing Operations of $7.5 million, or $1.17 per share, in Q3 of 2018. Diversicare completed its exit from the State of Kentucky effective on August 30, 2019 that consisted of 13 centers and 1,127 skilled nursing beds.

Mr. Jay McKnight, President and Chief Executive Officer of Diversicare Healthcare Services, said, "This quarter we successfully completed the exit of operations in the State of Kentucky, which is the latest of our larger initiatives. Over the past year we have undertaken major steps to improve our clinical offerings and risk profile, renew our largest operating lease, improve our operating cost structure, and work through our open government matter. Our team has been working very hard on these transformative events and I could not be more proud of them. We continue to explore opportunities to incrementally improve our current portfolio by focusing on improving revenue and the operational efficiency of our business.”

Diversicare Healthcare Services, Inc. (DVCR), closed Tuesday's trading session at $2.80, up 7.2797%, on 300 volume with 3 trades. The average volume for the last 3 months is 8,052 and the stock's 52-week low/high is $1.15999996/$2.99.

chart

HempAmericana, Inc. (HMPQ)

Stock of the Week, Epic Stock Picks, MicroSmallCap, The Wolf of Penny Stocks, TMXmoney, Stockwatch, InvestorsHub, Morningstar, OTC Markets, Wallet Investor, Stockhouse, and GlobeNewswire reported beforehand on HempAmericana, Inc. (HMPQ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

HempAmericana, Inc. researches, develops, and sells products made of industrial hemp in the U.S. The Company is an emerging participant in the CBD (cannabidiol) products market. It owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility in Augusta, Maine. The Company has its head office in New York, New York. HempAmericana’s shares trade on the OTC Markets.

The Company’s extraction and processing facility has a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. Furthermore, HempAmericana researches, develops, and sells products made of industrial hemp. This includes a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”.

HempAmericana’s CBD oil business uses the brand designation, “Weed Got Oil”. The Company continues to pursue an active place in the CBD white label market segment, particularly for those companies looking for premium full-spectrum distillate CBD oil.

In October, HempAmericana announced its forthcoming launch of its new Smokable Hemp Flower product line. It will launch the new product this month, with full packaging and distribution arrangements now being negotiated.

HempAmericana Chief Executive Officer, Mr. Salvador Rosillo, said, “The smokable hemp flower market has really started to take off according to our research, and we are extremely well-positioned to take advantage given our deep experience in hemp and hemp cultivation. This is a higher margin segment, given the lack of extraction and processing costs, and we plan to seize it with both hands. We already have the infrastructure to seamlessly move in this direction, and it represents, arguably, one of the most powerful applications of capital we might find anywhere right now, and perhaps for years to come.”

Recent research from the Brightfield Group concludes that the market for smokable hemp flower is projected to increase to $70.6 million this year. This is up from $11.7 million in 2018. This represents a year-over-year growth rate of greater than 500 percent. This significantly outpaces other segments of the overall CBD market.

HempAmericana, Inc. (HMPQ), closed Tuesday's trading session at $0.0047, even for the day, on 1,690,766 volume with 50 trades. The average volume for the last 3 months is 8,052 and the stock's 52-week low/high is $0.004399999/$0.027699999.

chart

Ionix Technology, Inc. (IINX)

Financial Content, Open Insider, Wallet Investor, YCharts, Barchart, Small Cap Exclusive, Stockopedia, Last10k, Dividend Investor, Current Charts, Market Exclusive, Wallmine, OTC Markets, Simply Wall St, Stockhouse, The Street, Morningstar, and MarketWatch reported previously on Ionix Technology, Inc. (IINX), and today we are highlighting Company, here at the QualityStocks Daily Newsletter.

Ionix Technology, Inc. is a business aggregator in photoelectric display and smart energy fields. It is concentrating on becoming the business aggregator that chiefly promotes photoelectric display, smart energy and lead industrial technology development since restructuring. Through incorporating high quality enterprises and innovating forward-looking technologies, Ionix provides more optimized green energy solutions. The Company previously went by the name Cambridge Projects, Inc. It changed its name to Ionix Technology, Inc. in February of 2016. Ionix Technology lists on the OTCQB.

Ionix has four operating subsidiaries. One is Changchun Fangguan Photoelectric Display Technology Co., Ltd. It specializes in developing, designing, producing, and selling TN and STN LCD, STN, CSTN, and TFT LCD modules and other related products. Another subsidiary is Shenzhen Baileqi Electronic Technology Co., Ltd. It specializes in LCD slicing, filling, researching and designing, manufacturing and selling of LCD Modules (LCM) and PCBs.

Subsidiary Dalian Shizhe New Energy Technology Co., Ltd., engages in photo-voltaic power generation, electric vehicles and charging piles with corresponding operation and maintenance and three-dimensional parking. Subsidiary Lisite Science Technology (Shenzhen) Co., Ltd., engages in the production of intelligent electronic devices. At present, the Company has embarked on the layout of industrialization and marketization of front end materials and back end modules of flexible folding liquid crystal displays by taking Changchun Fangguan and Shenzhen Baileqi as production bases, to capture the market share of OLED high technology.

In January 2019, Ionix Technology announced that it entered into certain VIE Transaction Documents with certain shareholders of Changchun Fangguan Electronics Technology Co., Ltd. Changchun Fangguan is a foremost manufacturer in the liquid crystal displays field. Through entering into specific VIE Transaction Documents, Ionix Technology acquired control of Changchun Fangguan.

Last week, Ionix Technology announced that its subsidiary Changchun Fangguan Electronics Technology Co., Ltd. reported unaudited revenue of $ 9.93 million for Q1 of the fiscal year 2020. This represents a 79 percent increase from $ 5.55 million last quarter.

Mr. Mr. Jialin Liang, Director of Ionix Technology and General Manager of Changchun Fangguan, said, "The significant revenue increase of Changchun Fangguan was mainly attributed to the expansion of sales channels and our continuous investment in technology. In 2019, the domestic ETC road traffic intelligent equipment and the bank U shield display were upgraded, the market demand for display screens continued to grow. Thanks to our technical strength and high quality of products, Changchun Fangguan received more production orders than the industry average."

Ionix Technology, Inc. (IINX), closed Tuesday's trading session at $1.90, even for the day, on 2,002 volume with 4 trades. The average volume for the last 3 months is 1,843 and the stock's 52-week low/high is $1.01999998/$2.75.

chart

Kona Gold Solutions, Inc. (KGKG)

Discovery Stocks, Micro Cap Daily, Talkmarkets, Trading View, Market Screener, 4-Traders, Clay Trader, Dividend Investor, InvestorsHub, Wallet Investor, Insider Financial, Stockwatch, Stockhouse, and Wallmine reported earlier on Kona Gold Solutions, Inc. (KGKG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Kona Gold Solutions, Inc. is a hemp and CBD (cannabidiol) lifestyle brand focused on product development in the functional beverage sector. The Company has created wholly-owned subsidiaries, Kona Gold LLC, HighDrate, LLC, and Gold Leaf Distribution, LLC. Kona Gold Solutions has its head office in Melbourne, Florida. The Company lists on the OTC Markets.

Subsidiary Kona Gold, LLC has developed a premium Hemp Infused Energy Drink line. The HighDrate, LLC subsidiary has developed the beverage industry’s first CBD Energy Water, available in four flavors. The Gold Leaf Distribution, LLC subsidiary was established to fill Kona Gold Solutions’ distribution needs in markets it wants to quickly enter.

Kona Gold Solutions has its new Hemp Energy Drink and CBD Energy Water flavors. Its Kona Gold Hemp Energy Drink line extension includes Bubble Gum and Candy Apple flavors. The line extension for its HighDrate CBD Energy Waters includes Blue Island Punch and Sour Apple.

Kona Gold Solutions has launched its aforementioned Bubble Gum and Candy Apple flavored hemp energy drinks. The announcement is coming off the success of its Cotton Candy and Cherry Vanilla flavors that went to market in late 2018 and continue to be Kona Gold’s top selling hemp energy drinks.

Recently, Kona Gold Solutions announced the launch of its all new Pink Grapefruit Hemp Energy Drink, Kona Pink. The Company recently announced its partnership with the American Breast Cancer Foundation where the two companies, in a collaborative effort, created a beautifully designed 12.0 oz can while Kona Gold formulated the Pink Grapefruit flavor. A portion of all proceeds from each Pink Grapefruit case sold will go to the American Breast Cancer Foundation to help provide financial assistance for breast cancer screenings, education, and support services to individuals who are uninsured and underserved.

Today, Gold Solutions announce it signed a distribution agreement with Alabama based AlaBev. AlaBev will distribute the Company’s Kona Gold Hemp Energy Drinks across the entire State of Alabama, placing the Company’s products in new important markets across the State. AlaBev is an Importer and DSD (Direct Store Delivery) Wholesale Distributor of beer, cider, wine, spirits and alcohol free beverages. Its coverage area is the State of Alabama.

Kona Gold Solutions, Inc. (KGKG), closed Tuesday's trading session at $0.068, up 7.9365%, on 2,120,517 volume with 172 trades. The average volume for the last 3 months is 3,346,397 and the stock's 52-week low/high is $0.039/$0.149399995.

chart

Westleaf, Inc. (WSLFF)

Pinnacle Digest, Wallmine, Trading View, Stockwatch, MarketWatch, Stock Target Advisor, Midas Letter, InvestorsHub, Investors Hangout, Technical420, Business Insider, Barchart, Investor Ideas, Insider Financial, Stockhouse, YCharts, and Morningstar reported beforehand on Westleaf, Inc. (WSLFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Westleaf, Inc. engages in the cultivation, extraction, distribution, and sale of cannabis and cannabis related products. The Company is a vertically integrated cannabis business. It has assets owned and under development across cultivation, extraction, processing, manufacturing, and wholly-owned retail. OTCQB-listed, Westleaf is headquartered in Calgary, Alberta.

The Company is developing a national presence of retail stores named Prairie Records. This is a brand that celebrates the instinctual tie between music and recreational cannabis. Prairie Records provides access to the nation’s best cannabis. It is a reinvention of the cannabis purchasing experience in a high design, sophisticated retail space, reflecting that of a contemporary record store.

Additionally, Westleaf’s brands include Loon Cannabis and Westleaf Cannabis. Loon Cannabis is a health and wellness cannabis line. The design of it is to help customers live their optimal lives, so they can thrive and enjoy life with clarity and peace of mind. Loon Cannabis has an array of calming strains and innovative products. Westleaf Cannabis created a signature brand of medicinal cannabis products for customers looking to treat symptoms of illness and other conditions. The design of these products is to help customers reduce pain or to moderate side effects from ongoing health conditions.

Westleaf has its e-commerce site for sales across the entire Province of Saskatchewan. The retail site, at www.prairierecords.ca, provides consumers in Saskatchewan convenient online access to a broad variety of products via the Prairie Records retail concept that combines music and cannabis in an engaging online experience. Prairie Records focuses exclusively on densely populated neighborhoods, high traffic areas, and tourist destinations.

Yesterday, Westleaf announced that the conditions precedent to the white-label cannabis derivative product sale agreement between the Company's wholly owned subsidiary Westleaf Labs LP and Delta 9 Cannabis, Inc. (NINE.V) (VRNDF) ("Delta 9") have been completed. Westleaf Labs received the initial order from Delta 9 for an initial three-month supply of vape pens and cartridges. This first order represents anticipated revenue of approximately $740,000 starting as early as January 2020.

This White-Label Agreement provides for Westleaf Labs to produce a minimum of roughly $4 million of white labelled cannabis derivative products, with the option to increase to $16 million per annum. The one-year agreement was announced on July 24, 2019. Westleaf Labs received its Health Canada Standard Processing Licence on October 11th and is ready to start processing.

Westleaf, Inc. (WSLFF), closed Tuesday's trading session at $0.228, up 4.1096%, on 30,181 volume with 12 trades. The average volume for the last 3 months is 49,862 and the stock's 52-week low/high is $0.194900006/$5.00.

chart

Bright Mountain Media, Inc. (BMTM)

Zacks, GlobeNewswire, Real Investment Advice, TMXmoney, Glassdoor, Capital Cube, Wallet Investor, InvestorsHub, Simply Wall St, Stockhouse, Last10k, TradingView, and Stockopedia reported earlier on Bright Mountain Media, Inc. (BMTM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Bright Mountain Media, Inc. is a digital media holding company. Its main emphasis is connecting brands with consumers as a full advertising services platform. The Company’s assets include an ad network, an ad exchange platform, and 25 websites (owned and/or managed) that provide content, services and products. Established in 2010, Bright Mountain Media has its corporate headquarters in Boca Raton, Florida.

The Company’s mission is to make sure publishers and content creators are fairly paid and that brands and advertisers get more return on their investment with Bright Mountain Media than anywhere else. The Company offers the latest in advertising technology. It has developed custom video ad units for its partners and shares their content to its millions of social media followers.

For advertisers, Bright Mountain Media combines custom content, astute social media, and powerful creative messaging on its platforms to propel supreme customer engagement with brands. It partners with a number of websites that reach a similar demographic allowing brands to reach more than 100 million monthly visitors. In addition, the Company has a core group of websites and social media pages that create content for a very specific group, America’s Heroes. Whether it be military, veterans, law enforcement, fire-rescue or their families, Bright Mountain Media can reach them.

The Company’s sites have 40 percent more visitors with household incomes above $100k than the United States average. Moreover, 84 percent of the visitors to its websites reside in the United States. In addition, the majority of its audience have children.

Recently, Bright Mountain Media announced that on June 10, 2019, it entered into an Agreement and Plan of Merger to acquire Inform, Inc. in an all-stock transaction. It was earlier announced that it entered into a non-binding Letter of Intent (LOI) with Inform, Inc. dated April 25, 2019. Inform (Atlanta, Georgia) provides data-driven technology solutions for the syndication and monetization of contextually relevant, personalized premium video content. The closing of the transaction, in which Bright Mountain Media will issue a maximum of 25 million shares of its common stock for all of the Inform, Inc. securities, is scheduled to close on August 30, 2019.

Earlier in August, Bright Mountain Media announced that on July 31, 2019, it entered into a Share Exchange Agreement and Plan of Merger to acquire Slutzky & Winshman Ltd. d/b/a/ S&W Media Group in a cash and stock transaction. It was earlier announced that it entered into a non-binding LOI with S&W dated May 23, 2019. S&W (Tel Aviv, Israel) is a data-driven marketing company that utilizes programmatic solutions for Over The Top, or OTT, video and mobile advertising.

Bright Mountain Media, Inc. (BMTM), closed Tuesday's trading session at $1.65, up 32.00%, on 216 volume with 3 trades. The average volume for the last 3 months is 304 and the stock's 52-week low/high is $0.200000002/$3.25.

chart

Zoom Telephonics, Inc. (ZMTP)

Simply Wall St, Zacks, GlobeNewswire, Stockopedia, Marketbeat, Investors Hangout, Equity Clock, MarketWatch, 4-Traders, YCharts, Whale Wisdom, Marketwired, Insider Tracking, Stockwatch, Stockhouse, InvestorsHub, Wallet Investor, GuruFocus, Market Screener, and Uptick Newswire reported previously on Zoom Telephonics, Inc. (ZMTP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Zoom Telephonics, Inc. is a foremost producer of cable modems and other communication products. Its global Motorola exclusive license agreement includes cable modems and gateways, DSL modems and gateways, cellular modems and routers, and other Internet and network products. The Company also sells USB cell modems and other communication products under its Zoom brand. OTCQB-listed and founded in 1977, Zoom Telephonics is headquartered in Boston, Massachusetts.

The Company’s Boston-based engineers design high-performance products that are user-friendly. Zoom Telephonics manages and supports its products from its Boston headquarters, carefully controlling the design and quality of the Company’s products. Zoom usually ships its products from San Diego, California.

Regarding Zoom OEM Solutions, system builders can purchase the Company’s modems and other products as bulk-pack products. In addition, Zoom offers volume sales, private-labeled products, as well as custom features. Moreover, Zoom products are approved for use in numerous countries worldwide. Also, many of the Company’s products come with user documentation and software in Spanish.

Zoom Telephonics provides cable modems, asymmetrical digital subscriber line modems, mobile broadband modems and routers, dial-up modems, local area network products, and mobile broadband sensors. The Company also provides embedded modems, ISDN modems, telephone dialers, wireless and wired networking equipment, phone jacks and AC power adapters, and language-related specifics.

Recently, Zoom Telephonics reported financial results for its 2018 Q4 and year ended December 31, 2018. Q4 Net Sales decreased 15.8 percent to $7.5 million with 2018 Net Sales increasing 9.9 percent to $32.3 million. Q4 Gross Margin decreased to 31.6 percent from 36.6 percent with 2018 Gross Margin increasing to 36.0 percent from 34.8 percent.

Q4 Net Loss was roughly $826,000, or $0.05 per share, versus a Net Loss of $387,000, or $0.03 per share, for Q4 2017. The 2018 Net Loss was $74,000, or $0.00 per share, versus a Net Loss of $1.37 million, or $0.09 per share, for 2017.

Zoom Telephonics, Inc. (ZMTP), closed Tuesday's trading session at $0.93, up 24.00%, on 51,055 volume with 29 trades. The average volume for the last 3 months is 4,566 and the stock's 52-week low/high is $0.621299982/$2.28999996.

chart

Mountain High Acquisitions Corp. (MYHI)

Wealth Insider Alert, SmallCapVoice, Wallstreet Profiler, FivedollarMovers, Stockgoodies, Laissez Faire Today, Integrity Solution IR, Cannabis Financial Network, TopPennyStockMovers, Market Intelligence Center, Charms Investments, StreetAuthority Daily, and PennyDoctor reported earlier on Mountain High Acquisitions Corp. (MYHI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.  

Mountain High Acquisitions Corp. is a turnkey, pioneering infrastructure provider to licensed cannabis growers, processors, and producers in regulated markets. The Company assists in the design, permitting, development, and operation of scalable infrastructure. OTCQB-listed, Mountain High Acquisitions is based in Scottsdale, Arizona.

Additionally, the Company helps licensed operators take advantage of scientific and technological innovations specifically geared to optimize the cultivation and processing of cannabis. In 2017, Mountain High Acquisitions entered into an agreement with D9 Manufacturing, Inc. D9 Manufacturing is an Arizona-based business that provides a wide variety of engineering, manufacturing, and consulting services to the cannabis sector.

Mountain High Acquisitions engaged D9 Manufacturing to assist in the identification, acquisition, and development of infrastructure and technology opportunities in the emerging cannabis market. Mountain High, together with D9 Manufacturing, has launched a pilot project targeted at proving a turnkey infrastructure model Mountain High intends to launch in highly promising cannabis markets. This includes California, Washington, and Arizona. The goal is to assist licensed cannabis growers in overcoming the key business challenge of financing steep start-up infrastructure expenses.  

   Mountain High Acquisitions has expanded its pilot program focused on providing turnkey infrastructure solutions to licensed cannabis growers. With the help of D9 Manufacturing, the program agenda has expanded to include the development of reliable Standard Operating Procedures (SOPs), which growers will be able to use to substantially reduce the risk of low yield or failed grows. D9 Manufacturing is concentrating on fine-tuning SOPs and best practices.

Mountain High Acquisitions announced in August of 2018 that it closed on the acquisition of One Lab Co. One Lab is a Nevada-based company that provides extraction equipment to the cannabis industry.

This past November, Mountain High Acquisitions announced that its wholly-owned subsidiary One Lab Co. completed delivery of a state-of-the-art modular extraction lab to Workforce Labor Solutions, LLC (WLS). WLS provides turnkey labor and extraction services to licensed cannabis producers in Washington State. According to the terms of the five-year lease with One Lab, WLS will make payments of $25,000 per month for use of the lab.

Mountain High Acquisitions Corp. (MYHI), closed Tuesday's trading session at $0.0085, up 25.00%, on 54,255 volume with 18 trades. The average volume for the last 3 months is 4,566 and the stock's 52-week low/high is $0.0065/$0.068000003.

chart

Nutra Pharma Corp. (NPHC)

Serious Traders, PennyStocks24, StocksToBuyNow, Pumps and Dumps, Winston Small Cap, Streetwise Reports, MyBestStockAlerts, BUYINS.NET, UndiscoveredEquities, Wallstreetlivechat, and Innovative Marketing reported earlier on Nutra Pharma Corp. (NPHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Nutra Pharma Corp. is a biotechnology company listed on the OTC Markets. The Company specializes in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. These include Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Nutra Pharma is marketing Nyloxin® and Pet Pain-Away™ in the Over-the-Counter (OTC) pain management market. Founded in 2000, Nutra Pharma is based in Coral Springs, Florida.

By way of its subsidiaries, the Company carries out basic drug discovery research and clinical development. The focus of its approach to drug discovery and the development of new therapeutic agents are based on specialized receptor-binding proteins found in nature, particularly those found in snake venom from the cobra.

Nutra Pharma’s leading drug candidates are RPI-78M and RPI-MN. Its MS drug RPI-78M was earlier granted Orphan Status by the Food and Drug Administration (FDA) for the treatment of Pediatric Multiple Sclerosis. Nutra Pharma’s RPI-MN inhibits the entry of many viruses known to cause severe neurological damage in diseases such as encephalitis and AIDS. RPI-MN is undergoing development initially for the treatment of HIV. RPI-78M is undergoing development for the treatment of multiple sclerosis (MS).

Additionally, Nutra Pharma looks for strategic licensing partnerships to reduce the risks associated with the drug development process. The Company’s holding, ReceptoPharm, is developing technologies to produce drugs for HIV and MS.

Nutra Pharma’s Designer Diagnostics subsidiary engages in the research and development (R&D) of diagnostic test kits designed to be used for the quick identification of infectious diseases. These include Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Nutra Pharma offers several drug products for sale for pain treatment. One is Nyloxin®, the first OTC pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The Company has launched Luxury Feet. This is a new version and packaging of its OTC pain drug Nyloxin. Another product is Nyloxin Extra Strength. This is the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Moreover, the Company has its Pet Pain-Away. This is the first OTC product to treat pain in companion animals without side effects. Pet Pain-Away is a homeopathic, non-narcotic, non-addictive, OTC pain reliever.

In September 2018, Nutra Pharma announced that its work with EuroAmerican IP, LLC resulted in a listing of its Nyloxin® product line on the website, www.GoVets.com. GoVets is the online marketplace under the National Veteran Small Business Coalition (NVSBC) to buy from VA-verified Service-Disabled Veteran-Owned Small Businesses (SDVOSBs).

With growing concern regarding consumers using opioid and acetaminophen-based pain relievers, Nyloxin® offers an alternative, which does not rely on opiates or non-steroidal anti-inflammatory drugs, known as NSAIDs, for their pain relieving effects. Nyloxin® has a well-defined safety profile.

Nutra Pharma Corp. (NPHC), closed Tuesday's trading session at $0.0003, up 50.00%, on 4,450,168 volume with 9 trades. The average volume for the last 3 months is 3,547,815 and the stock's 52-week low/high is $0.000199999/$0.0006.

chart

ReelTime Rentals, Inc. (RLTR)

MarketWatch, Stockhouse, Marketwired, WalletInvestor, Penny Stock Hub, Barchart, Simply Wall St, Penny Stock Tweets, 4-Traders, InvestorsHub, and OTC Markets reported on ReelTime Rentals, Inc. (RLTR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ReelTime Rentals, Inc. (d/b/a ReelTime VR, ReelTime Media Group) is a multimedia publishing business. The Company engages in helping individuals that have been thrust into the public eye to monetize their exposure and control the portrayal of their story. In addition, it develops, produces, and distributes Virtual Reality (VR) Content and technologies under the brand ReelTime VR. ReelTime is headquartered in Seattle, Washington and lists on the OTC Markets.

ReelTime has end to end production, editing, and distribution capabilities for internal and external projects. At present, the Company produces three ongoing series for the Samsung Gear VR platform, VeeR TV, Oculus. It distributes them over manifold VR delivery sites.

Regarding Partnerships, ReelTime partners with other top VR distributors, content producers, and technology providers. Furthermore, concerning its Services, the Company offers Consulting, Production, Monetization, VR Set Design, VR Media Campaigns, as well as VR Content Production.

Pertaining to VR Set Design, ReelTime has a totally-dressed virtual set in its studio facilities. It can create any look one wants for their Virtual Reality show. Also, it can provide traditional virtual set backdrops.

Concerning VR Content Production, ReelTime has a team of editors and other pre/post-production professionals available for all elements of producing VR content. This is from the initial design concepts, to pixel-perfect deliverables.

ReelTime VR announced recently that it became the first to utilize a proprietary technology developed by the Company that allows it to film in full 360 x 360 Virtual Reality formats and simultaneously film in formats compatible with traditional Television platforms. This will allow ReelTime VRs shows the Company produces to not only be available on the rapidly growing premium VR sites it is currently available on, but it will additionally be available for distribution over mainstream Network Television formats and worldwide.

ReelTime has received patent-pending status from the United States Patent and Trademark Office (USPTO) for its non-provisional patent application encompassing apparatus and method claims for technology involving simultaneous capturing of 360 X 360-degree Spherical Panorama Images and Video. The technology will enable any cell phone or other camera to promptly capture 360 X 360 Virtual Reality Video or pictures without any need for stitching.

The VR content is compatible with and can be shared through 360 capable social sites in real time, and on any professional VR platform such as Oculas, Gear VR, Veer VR, Playstation VR, Littlstar, and the HTC Vive.

ReelTime will start using this inventive technology in its production of its award-winning Virtual Reality travel series “In Front of View”. The series commenced filming its second season in Thailand in July. It is shot in English and in Thai. Moreover, ReelTime VR is entertaining licensing agreements with select other VR, film, and TV producers to allow them to also gain a competitive advantage.

ReelTime Rentals, Inc. (RLTR), closed Tuesday's trading session at $0.013536, up 73.9622%, on 241,530 volume with 9 trades. The average volume for the last 3 months is 151,453 and the stock's 52-week low/high is $0.002799999/$0.032000001.

chart

Graphene 3D Lab, Inc. (GPHBF)

OTC Markets, Agora Financial, and Stockhouse reported on Graphene 3D Lab, Inc. (GPHBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Graphene 3D Lab, Inc.,  via its wholly-owned subsidiary, Graphene Laboratories, Inc.,  develops, manufactures, and markets proprietary graphene-based nanocomposite materials for varied kinds of 3D printing. This includes fused filament fabrication. In addition the Company engages in the manufacture and sale of graphene materials and nanocomposite enhanced polymers through Graphene Laboratories.

Last week, Graphene 3D Lab announced that it completed its facility move to the new industrial facility at 760 Koehler Avenue, Ronkonkoma, State of New York. The 8,000 sq. ft. facility is in a tech park close to Long Island MacArthur Airport. It is approximately 30 miles from Graphene 3D Lab’s former Calverton facility.

The Company’s go-to-market product is Conductive Graphene Filament. Conductive Graphene Filament brings users the ability to 3D print circuitry and sensors for electronic applications.  Graphene 3D Lab has its Industrial Materials Division to commercialize graphene composite materials. Graphene is a single-layer of carbon atoms. Graphene is considered a wonder-material for its high strength, conductivity, and ultra-light-weight. 

  Furthermore, Graphene 3D Lab  engages in the design, manufacture, and marketing of 3D printers and related products for domestic and  international customers.  It focuses on the development and commercialization of technologies that improve the capabilities of 3D printing.

The Company’s 3D printing division provides a suite of specialty fused fabrication filaments.  In addition,  Graphene 3D Lab owns a new proprietary technology encompassing the preparation and separation of graphene's atomic layers. 

  Graphene 3D Lab announced in 2017 the commercial release of two new additions to the G6-Epoxy™ product line of advanced adhesive materials. The product line includes unique carbon-silver adhesive materials. These are built on technology that has undergone development by the Company’s Industrial Division. The new epoxies are highly electrically conductive adhesives with a proprietary formula based on the combination of graphene and silver fillers and other additives. 

  Graphene 3D Lab has released the Graphene-HIPS 3D Printing Filament. Graphene-HIPS is a distinctly engineered and innovative semi-flexible FDM 3D Printing material reinforced with graphene. The design of it is for high performance 3D printing. The FDM material exhibits premier interlayer adhesion, toughness, and also premier impact resistance.

In February, Graphene 3D Lab announced it filed a patent application entitled "Method and System for Recovering and Utilizing Heat Energy Produced by Computer Hardware in Blockchain Mining Operations" with the United States Patent and Trademark Office (USPTO). This invention introduces a pioneering new technology for recuperating the thermal energy produced in the computation and Blockchain operation, using that recovered thermal energy in heating and/or refrigeration modules utilizing graphene.

With the method invented by Graphene 3D Lab, the thermal energy produced by the computational hardware is harvested and converted into heating and/or refrigeration solutions with modules utilizing graphene. The solutions can be used for air conditioning or food preservation. Therefore, this lessens electric energy consumption while supporting the Blockchain network or cryptocurrency mining.

Graphene 3D Lab, Inc. (GPHBF), closed Tuesday's trading session at $0.04088, up 28.959%, on 138,600 volume with 18 trades. The average volume for the last 3 months is 50,915 and the stock's 52-week low/high is $0.028/$0.079999998.

chart

Eco Science Solutions, Inc. (ESSI)

Wall Street Mover, ThePUMPTracker, DSR News, Real Pennies, Promotion Stock Secrets, TopPennyStockMovers, Wallstreetlivechat, and Pumps and Dumps reported earlier on Eco Science Solutions, Inc. (ESSI), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Eco Science Solutions, Inc. is an eco-technology Company with its corporate headquarters in Makawao, Hawaii. It provides solutions to the multi-billion-dollar health, wellness, and alternative medicine industry. Eco Science Solutions develops technical solutions - from enterprise software solutions, to consumer applications (apps) for daily use. These solutions energize enthusiasts in their pursuit and enjoyment of building eco-friendly businesses and living healthy lifestyles. Eco Science Solutions’ shares trade on the OTC Markets Group’s OTCQB.

Eco Science Solutions’ key services cover localized communications between consumers and business operators, social networking with like-minded enthusiasts, rich educational content, e-commerce, and fast delivery of products. These all cater to the health-and-wellness lifestyle.

The Company’s brands include Herbo, Fitrix, and pHion Balance. The Herbo app assists consumers in finding products and services that support the intake of alternative medicines for a more naturopathic lifestyle. Herbo has a database of greater than 14,000 alternative medicine locations and delivery services, doctors who provide evaluations, and local shops that sell relevant product.

The Fitrix app is a strong and flexible companion. Fitrix assists users’ in keeping track of their day-to-day fitness routines, dietary habits, and alternative medicine intake. Fitrix users can measure and track anything and everything concerning their health and wellness.

The Company’s pHion Balance underwent development to create nutritional supplements, which support and promote a healthy lifestyle. pHion Balance is centered on developing nutritional supplements that take the guesswork out of supplementing the body in the healthiest way.

Eco Science Solutions will continue to make investments in e-commerce and mobile applications that facilitate B2C (Business-to-Consumer) e-commerce opportunities.

Last year, Eco Science Solutions' main projects focused on continued consumer and enterprise technology investment; continued product formulation and inventory build for distribution; and strategic acquisitions, which provide an accelerated time-frame to obtain market share.

In May of 2017, the Company announced that it signed a Sponsorship, Content Development, and Licensing agreement with Roaring Lion Tours, Inc. Roaring Lion Tours develops inspirational and educational content that further promotes what it believes are the benefits of medical marijuana.  This agreement is to develop unique educational content that brings awareness and education to the alternative medicine category.

Eco Science Solutions, Inc. (ESSI), closed Tuesday's trading session at $0.0301, up 201.00%, on 2,756 volume with 10 trades. The average volume for the last 3 months is 8,318 and the stock's 52-week low/high is $0.000009999/$0.360000014.

chart

The QualityStocks Company Corner

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from NetworkNewsWire, examining how, despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target deadly ovarian cancers.

Predictive Oncology (POAI) is a data and artificial intelligence-driven discovery services company that provides predictive models of tumor drug response to improve patient outcome. Predictive Oncology harnesses the power of artificial intelligence, collaborating with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for patients, which can lead to much more effective treatments.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable development of patient specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Predictive Oncology (POAI), closed Tuesday's trading session at $4.4828, up 2.1139%, on 75,117 volume with 428 trades. The average volume for the last 3 months is 8,878 and the stock's 52-week low/high is $3.31999993/$8.50.

Recent News

chart

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) was featured today in a publication from HempWireNews, examining how Virginia’s first commercial hemp fiber processing plant, Vitality Farms, LLC, will soon be launched in Wythe County according to an announcement Governor Ralph Northam. The facility, currently operating as Appalachian Biomass Processing, plans on investing $894,000 and creating 13 jobs.

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Tuesday's trading session at $3.45, up 5.8282%, on 1,580,215 volume with 5,587 trades. The average volume for the last 3 months is 1,338,815 and the stock's 52-week low/high is $2.71000003/$8.43999958.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTC:LXRP) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is very pleased to announce the appointment of Gregg Smith, Founder of Evolution VC Partners (www.evolutionvcp.com), as Senior Advisor. Evolution VC is a New York-based "culture tech" venture investment firm with more than 90 portfolio companies in many disruptive and emerging consumer-tech companies, including JUUL Labs, Pax Labs, Beyond Meat, Roman, Sweetgreen, Bird, New Wave Foods, Relativity Space and more. Also today, the company was highlighted in a publication from TheNewswire, examining the announcement of having issued certain stock options. Pursuant to certain consulting agreements recently entered into by the Company, Lexaria is issuing a total of 1,000,000 stock award options ("Options"), whereby each Option is valid to purchase one common share ("Share") at a price of US$0.55 per Share for a period of five years; and 225,000 share purchase warrants ("Warrants"), each Warrant being valid to purchase one Share at a price of US$0.80 for a period of three years.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hmep-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Tuesday's trading session at $0.6049, up 12.0393%, on 143,401 volume with 81 trades. The average volume for the last 3 months is 88,047 and the stock's 52-week low/high is $0.399800002/$1.70000004.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) was highlighted today in a publication from Financialnewsmedia.com, examining how research into psychedelics for the treatment of anxiety, depression, and other mental illnesses has only begun to expand – and investors are excited. Studies have already shown that when it’s “ingested it transforms into a psychoactive chemical in the body that might help dramatically reduce symptoms of depression, messing with the brain’s pre-frontal cortex, which affects our mood and perception of things and another part of your brain, that’s a part of processing emotional reaction to fear and anxiety,” as reported by Spectrum News.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Tuesday's trading session at $0.5317, up 3.323%, on 245,155 volume with 265 trades. The average volume for the last 3 months is 514,430 and the stock's 52-week low/high is $0.479999989/$1.7888.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood Holdings (OTCQB: NGTF), the innovative company addressing America’s $50 billion annual night snacking spend, today announced that the company has engaged Independent Natural Food Brokers (“INFB”) to represent the Nightfood line to retail accounts throughout the western half of the United States. To view the full press release, visit http://nnw.fm/orS6W

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Tuesday's trading session at $0.283, up 4.8148%, on 89,603 volume with 34 trades. The average volume for the last 3 months is 146,760 and the stock's 52-week low/high is $0.160099998/$0.920000016.

Recent News

chart

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF)

The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: IONKF).

IONIC Brands (CSE: IONC) (OTC: IONKF) (FRA: IB3), a Tacoma, Washington-based cannabis holding company, recently acquired Zoots Premium Cannabis and its assortment of drops, gummies, energy shots and hard candies (http://cnw.fm/DeI1B). To view the full article, visit http://cnw.fm/dGO9q.

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in leading markets across the western United States, with current operations in Washington, Oregon, California and Nevada. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC’s product lines are pioneering the changing landscape of cannabis consumption. The company’s refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC’s Certified Clean program verifies that every product leaving the company’s facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green’s technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package’s QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company’s flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC’s immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC’s expansion and development into Washington state’s leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck’s.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC’s aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the “Top 50 Companies to Work for in Cannabis” by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: IONKF), closed Tuesday's trading session at $0.02657, up 10.7083%, on 69,740 volume with 18 trades. The average volume for the last 3 months is 146,760 and the stock's 52-week low/high is $0.019999999/$0.634559988.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

A diversified holding company, SinglePoint Inc.’s (OTCQB: SING) largest acquisition to date has definitely paid off. Acquired by SING in May, Direct Solar posted record sales in its first 60 days with the company, added a new division to reach untapped markets, and signed a partnership with one of the fastest-growing real-estate brokerages in the nation. Based on the subsidiary’s performance thus far, SinglePoint is forecasting record sales for this year, with even higher numbers projected for 2020.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Tuesday's trading session at $0.01134, up 1.25%, on 2,368,656 volume with 97 trades. The average volume for the last 3 months is 2,734,179 and the stock's 52-week low/high is $0.009999999/$0.028999999.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Commercial-stage developer of innovative medical devices Endonovo Therapeutics (OTCQB: ENDV) recently named Dr. William Li, CEO and co-founder of the Angiogenesis Foundation, as a strategic advisor to the CEO. To view the full article, visit http://nnw.fm/sr3bO

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Steven C. Levin, M.D., Scientific Advisory Board Member
Dr. Steven C. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology. Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. Additionally, Dr. Levin has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center. Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.

Peter Novak, M.D., Ph.D., Scientific Advisory Board Member
Dr. Peter Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

Geoffrey Abrams, M.D., Scientific Advisory Board Member
Dr. Geoffrey Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for Stanford’s varsity athletes. He specializes in orthopedic sports medicine and arthroscopy of the shoulder, knee and elbow as well as upper extremity joint replacement surgery. Dr. Abrams is a member of the American Academy of Orthopedic Surgeons (AAOS) and the American Orthopedic Society for Sports Medicine (AOSSM), among others, and currently serves as assistant team physician for the NFL’s San Francisco 49ers as well as head team physician for a number of Stanford University varsity athletic teams. He is actively involved in research focusing on the role of inflammatory mediators, and microRNA in particular, on cartilage and tendon damage. Dr. Abrams received his undergraduate degree from Stanford University and his doctorate of medicine from the University of California – San Diego. He completed his residency in orthopedic surgery at Stanford University and went on to receive additional training in Orthopedic Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Abrams has authored or co-authored over 60 peer-reviewed scientific articles, over 20 book chapters, has presented original research at numerous national and international scientific meetings, and serves as a reviewer for numerous sports medicine scientific journals.

Dr. William Li, Scientific Advisory Board Member
Dr. William Li is CEO and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies. Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost-effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.

Mykol Larvie, Scientific Advisory Board Member
Recipient of three Harvard Medical Student Teaching awards in Principal Clinic Experience, Mykol Larvie is currently a radiologist in the Cleveland Clinic’s Divisions of Nuclear Medicine and Neuroradiology as well as the director of Functional and Molecular Neuroimaging. With a completed internship in the Department of Medicine as well residency in the Department of Radiology and fellowship in the Division of Neuroradiology at the Massachusetts General Hospital, Dr. Larvie specializes in PET examinations of the brain performed typically for the evaluation of neurodegenerative disease, seizure and tumor. He delivers didactic lectures and case conferences to residents and fellows six times per year and serves as a mentor and advisor to medical students, residents and fellows.

Nathan L. Guerette, Scientific Advisory Board Member
Nathan L. Guerette is the director and president of the Female Pelvic Medicine Institute of Virginia; an associate clinical professor in the division of Urogynecology and Pelvic Reconstructive Surgery at the Medical College of Virginia; a full clinical professor in Urogynecology and Pelvic Reconstructive Surgery at the Riverside Regional Medical Center; and the Robotic Surgery director at the Chippenham and Johnston Willis Medical Center. With a completed fellowship in urogynecology and pelvic reconstructive surgery at the Cleveland Clinic Foundation, Dr. Guerette has won seven awards in the medical and humanitarian departments. He has made nine media appearances, some of which were on PBS and NBC News. He has three board certifications and has ran a surgical mission trip to Trujillo, Peru, through Bon Secours.

Dr. Ashling O’Connor, Scientific Advisory Board Member
Currently a surgeon at the Comprehensive Breast Health Center of the Lahey Medical Center, Dr. O’Connor has won seven awards in the surgical department. She has completed a surgical internship at the Mater Misericordiae Hospital in Dublin as well as a breast surgery fellowship at the University of Massachusetts Interdisciplinary Breast Fellowship. She mentors medical students and surgical residents both in the operating room and in a clinical setting and enjoys biking and triathlons as well as trail and marathon running. She is certified in the Hidden Scar technique in breast surgery as well as in the advanced cardiac life support and is a member of the Protocol Review Committee Umass Memorial Medical Center, the New England Surgical Society and the American College of Surgeons.

Samir Awad, Scientific Advisory Board Member
Samir Awad has worked for the Department of Veterans Affairs since 2000. He has served as the operative care line associate executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad’s areas of specialty include liver, pancreas, and acute care surgery, as well as minimally invasive surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine. Dr. Awad has authored more than 100 peer-reviewed and invited publications and is the recipient of numerous awards for surgical and research achievements. Dr. Awad is certified by the American Board of Surgery and Surgical Critical Care.

Endonovo Therapeutics Inc. (ENDV), closed Tuesday's trading session at $0.0055, up 1.8519%, on 9,498,345 volume with 81 trades. The average volume for the last 3 months is 2,734,179 and the stock's 52-week low/high is $0.0035/$0.043999999.

Recent News

chart

InsuraGuest Inc.

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Inc..

InsuraGuest Inc. delivers insurance using its proprietary InsurTech software platform. This enables both hotels and vacation rental properties to provide protection for their guests. Vacation rentals and hotels can buy the InsuraGuest protection policy, which the property extends the insurance coverage to their guests while on the property. People who plan to travel overseas or go on vacation are often encouraged to buy travel insurance to provide some protection from illness or accidents that may occur while traveling or visiting another country, but these policies may exclude or may be limited for accidents that happen at a vacation rental property or hotel. Even when traveling within a country, a person may find that their travelers’ policy does not cover what they thought it did, which puts them at risk for additional expenses.

InsuraGuest Inc. is a SaaS (Software-as-a-Service) company utilizing its proprietary flagship InsurTech software platform to provide specialized insurance products to end users in the business-to-business (B2B) and business-to-consumer (B2C) markets. The company’s first focus is on the B2B hotels and vacation rentals sectors, where its API integrates with the clients’ property management systems to offer guests a specialized guest protection policy. The platform and policy combination “InsurTech” product helps transfer the exposure to liability away from the client/property while guests benefit from potential accident and loss coverage during their stay.

InsuraGuest’s platform is currently capable of integrating with approximately 70 different hotel and vacation rental property management systems, giving it access to roughly 40,000 properties worldwide.

The company continues to pursue expansion opportunities and recently signed a Letter of Intent with a master general agent in the United Kingdom and Europe to distribute its platform and products to hotel and vacation rental markets in those regions, as well as plans to expand to Asia in 2020.

Protecting Guests, Enhancing Customer Experience

InsuraGuest is the first line of defense for both the property and the guest.

InsuraGuest is purchased by the hotel or vacation rental “property,” which offers the policy to each registered guest and its occupants for an additional fee. The specialized policy affords coverage for theft of personal property while in the hotel, as well as accidental medical expense and accidental death and dismemberment, up to the policy limits of $2,500 to $50,000.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United State alone, where there are approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s demographics combined will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Specialized Guest Protection Policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Business Highlights

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a BS undergraduate degree in Consumer Studies with an emphasis in Architecture as an undergraduate at the University of Utah. He subsequently earned his Master’s in Business Administration. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends.

Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Christopher J. Panos Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018. He also has served as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.


Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW) (OTCQB: CANSF) today announced that it has been approved to commence trading on the OTCQB® Venture Market (the "OTCQB"), under the symbol "CANSF," beginning today, November 5, 2019. The listing will enable Willow Biosciences access to a broader base of U.S. To view the full press release, visit http://cnw.fm/gQU9a.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Tuesday's trading session at $0.68, off by 2.86%, on 67,900 volume with 34 trades. The average volume for the last 3 months is 92,204 and the stock's 52-week low/high is $0.529999971/$5.25.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com Inc. (OTCQB: CIIX), a provider of financial information and services to a global Chinese speaking community, has made a concerted effort to expand its core investor relations (IR) and public relations (PR) service offerings while also constructing a presence in the expanding CBD industry. Also today, the company was highlighted in a publication from HempWireNews, examining how CEO Warren Wang recently discussed the focus of the company on “MoneyTV” with Donald Baillargeon (http://cnw.fm/6yrEt). To view the full article, visit http://cnw.fm/94urZ

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Tuesday's trading session at $0.191, off by 12.7854%, on 32,397 volume with 15 trades. The average volume for the last 3 months is 42,740 and the stock's 52-week low/high is $0.170000001/$0.689999997.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US: TGODF), a leading producer of premium certified organic cannabis, announced today that the Company expects to release its third quarter 2019 earnings on Thursday, November 14, 2019 after market close. The Company will hold a conference call conducted by Brian Athaide, Chief Executive Officer, and Sean Bovingdon, Chief Financial Officer, on November 15, 2019 at 9:00 am Eastern Time to discuss the results and future outlook. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how research into psychedelics for the treatment of anxiety, depression, and other mental illnesses has only begun to expand – and investors are excited. 

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Tuesday's trading session at $0.803, off by 1.7497%, on 673,254 volume with 497 trades. The average volume for the last 3 months is 1,071,656 and the stock's 52-week low/high is $0.685999989/$4.38000011.

Recent News

chart

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF)

The QualityStocks Daily Newsletter would like to spotlight Wonderfilm Media Corporation (OTC: WDRFF).

Wonderfilm Media (TSX.V: WNDR) (OTCQB: WDRFF), a producer of high-quality feature films and episodic television with international appeal, today announced a new first for the company. According to the update, the combined producer team of Kirk Shaw, Shaun Redick, Yvette Yates, Dan Grodnik, Bret Saxon and Jeff Bowler (the “Team”) is attending this year’s American Film Market (“AFM”) in Santa Monica, California from November 6-13. Also today, NetworkNewsWire released a report highlighting the company which examines the recent news that, as video streaming grows to dominate media consumption, companies are on the lookout for new ways to profit from the burgeoning trend.

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF) main business is the worldwide production of high-quality feature films and episodic television. The Wonder?lm team includes Hollywood veterans who have packaged, produced and delivered several profitable recent films, including “BlacKkKlansman,” “Get Out” and “The Hurt Locker.” Having these individuals on the Wonderfilm team demonstrates the company’s proven access to Academy Award-quality films and upside.

Wonder?lm maintains a continuing $58 million annual production slate to meet the constant and growing need for content worldwide. The company’s risk-averse production process results in predictable and consistent revenue streams.

Soaring demand for content from streaming providers is fueling industry growth. The global media and entertainment market is expected to grow from $1.9 trillion in 2017 to $2.4 trillion in 2022, a five-year CAGR of 4.4%.

The company recently formed Wonderfilm Global, an international film and television sales and distribution joint venture that is expected to generate significant incremental revenue.

Wonderfilm has strong relationships throughout the entertainment industry, which enables cost-effective production budgets and in-demand content creation.

Management Team with Proven Track Records

Kirk Shaw: Over 240 movies and seven television series to his credit. Headed up Canada’s largest independent film and television production company, attaining $100 million revenue two years straight with 8% EBITDA.

Dan Grodnik: Founded Mass Hysteria Entertainment, a publicly traded company, and became its chairman/CEO. Produced over 50 feature films, including “Bobby,” the 2006 Robert Kennedy biographic film.

Shaun Redick & Yvette Yates: $300 million+ USD total production budgets to date with a combined 175 award wins/355 nominations, including 10 Oscar nominations. In 2017 and 2018, they produced two of the most successful Hollywood films of those years: “Get Out” ($255 million USD gross revenue) and “BlacKkKlansman” ($100 million USD gross revenue). Scheduled to produce two to three films per year for Wonderfilm, with the first release slated for October 2020. Committed to the 4% challenge to give more women and women of color the opportunity to direct.

Jeff Bowler: 2017 Emmy Award-winning producer. Vice president of acquisitions and production for The Exchange, one of the top film sales and finance companies in the world. Bowler is the executive for Wonderfilm Global distribution.

Bret Saxon: Through his company, TMP Inc., Saxon created M&A deals worth over US$750 million across 113 countries. Produced several feature films and made-for-television movies, including Wonderfilm’s 2019 movie “Zombie Tidal Wave” for NBC/Universal’s SYFY.

17-Title Movie Slate — Greenlit

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few.

Some of the company’s most notable greenlit projects include the horror film “Amityville 1974,” slated for theatrical release in October 2020, and the action film “Inside Game” starring Tyrese Gibson, which will be released to theaters in fall 2020.

The company is also actively developing a number of other new IP projects, including a dramatic biographic feature titled “Life and Times of Steve McQueen,” a film adaptation of the bestselling novel “Merchant of Death” and a television series headed by “CSI: Crime Scene Investigation” creator Anthony Zuiker.

 

Potential for Breakout Success

Wonderfilm movies have the potential for millions of dollars in revenue from the kind of breakout success generated by films like “Saw” and “Get Out,” which would propel Wonderfilm and its revenue streams to a new level. Wonderfilm has several potential breakout films in its development/production queue.

Note: Potential breakout films are not factored into company’s revenue projections.

Base Hits and Home Runs

In tandem with its slate of high-profile films, Wonder?lm continues to finance, produce and deliver many profitable low-risk, lower-budget films that are base hits. Shaun Redick is a home run hitter, and his upcoming Wonderfilm projects are anticipated to be home run hits for the company, while base hits such as “Zombie Tidal Wave” provide a consistent source of revenue.

Recent Industry Breakout Films Include:

  • SAW – $1.2 million budget = $103.9 million in sales
  • Pulp Fiction – $8 million budget = $212 million in sales
  • My Big Fat Greek Wedding – $5 million budget = $250 million in sales
  • Lost in Translation – $4 million budget = $120 million in sales
  • Get Out – $4.5 million budget = $255.5 million sales (Shaun Redick)

Note: Revenue from most of Wonderfilm’s current slate will be recorded on the books in 2020 or 2021.

Recent Wonderfilm Releases

  • Aug. 17, 2019: Co-produced with NBC/Universal, “Zombie Tidal Wave” premièred on the SYFY channel to strong ratings.
  • Aug. 29, 2019: “The Fanatic” starring John Travolta opens in U.S. theaters.
  • Sept. 5, 2019: “Tammy’s Always Dying” premiers at Toronto Film Festival.
  • Nov. 8, 2019: “Primal” starring Nicolas Cage opens in U.S. theaters.

Wonderfilm Global Distribution

At the 2019 Cannes Film Festival, Wonderfilm officially launched Wonderfilm Global, a new film, television and media foreign sales/distribution joint venture with 101 Films and Paul McGowan.

Wonderfilm acquired 51% ownership in the joint venture structure and immediately began attaching its own productions to Wonderfilm Global. The joint venture represents a significant opportunity for Wonderfilm, changing how the company does business.

The intention behind Wonderfilm Global is to keep distribution margins in-house that previously went to other companies. Since most Wonderfilm movies are relatively low-risk and easy to sell because they feature desirable cast and genre, third-party distribution companies were previously earning approximately 10%, plus expenses, on Wonderfilm movies without any level of risk. Now, revenue is generated through presales of Wonder?lm projects and, at times, third-party films. The average Wonder?lm movie is pre-sold for $5million, garnering $500,000 to $750,000 per sale as a commission. These commissions now stay in-house with Wonder?lm Global, and the company expects to sell 10 to 12 third-party films between fall 2019 and fall 2020, generating roughly $6 million in commission income.

A further revenue source is generated from theatrical sales through a 50/50 upside split once the minimum sales threshold is met.

Wonder?lm Global has offices in Vancouver, Beverly Hills, London, Ireland, Seoul and China.

Wonderfilm Business Model

Wonderfilm productions are structured to begin generating a return to the company as soon as the camera starts rolling.

Return Before a Film is Delivered: Producer fee line items are included in each production budget. These range from $50,000 to $500,000, depending on the total budget, and are paid to Wonderfilm most commonly on the first day of principle photography.

Distribution: Wonderfilm Global charges sales and distribution fees within each production budget to cover its presale costs.

Note: Wonderfilm’s productions are all structured to minimize risk by matching budget to funds available.

Return After a Film is Delivered: Unsold presale territories are countries or territories left off of a film’s presale list, either for strategic reasons or because the broadcaster/distributor is waiting to see the completed film. These outside-the-budget distribution sales become Wonderfilm profit centers.

Sales overages once contracted presale threshold is surpassed.

The company’s film library grows with each new production, adding to future sales revenue. Depending on the agreement, exploitation rights for future worldwide sales return to Wonderfilm four or seven years after delivery. As of October 2019, Wonderfilm’s growing film library comprises 18 titles for future exploitation.

Note: The nature of the film business is that box office revenue lags production up to a couple of years.

$50 Million Wonderfilm Production Fund (WPF):

Wonderfilm is in the process of raising $50 million to establish a Wonderfilm Production Fund (WPF). WPF is designed to consolidate traditional production financing models into a single diversified, asset-backed debt instrument.

The WPF is a highly specialized investment vehicle with noncorrelated market returns normally reserved for institutional banks and specialty lenders, and it would pay 8% interest directly from each Wonderfilm movie or series budget and not from corporate funds. These same interest payments are already added to each production budget, as the company currently closes a separate financing for every film. The WPF would significantly streamline Wonderfilm’s production rate, adding revenue more quickly and broadening the yearly production slate.

For fund investors, the WPF is a dedicated production-financing vehicle designed to offer a risk-moderated approach to investing in film finance. The managed process provides structure and reassurance that are normally experienced only when working with an institutional lender that has a dedicated staff and resources.

All projects being financed are for Wonderfilm productions, with the fund collateral fully secured by receivables, including presale contracts, government incentives, or a guarantee from Wonderfilm for any unsecured amounts as may be permitted.

Wonderfilm Media Corporation (OTC: WDRFF), closed Tuesday's trading session at $0.132, off by 9.4029%, on 19,266 volume with 7 trades. The average volume for the last 3 months is 62,281 and the stock's 52-week low/high is $0.075099997/$0.504400014.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Infrastructure real-estate investment trusts (REITs) often play key roles in a community’s technological progress and advancement. As 5G technology rolls out, these organizations are looking to continue their invaluable involvement and support, which benefits companies such as Spectrum Global Solutions Inc. (OTCQB: SGSI)that are involved in 5G development. Spectrum is a leading provider of comprehensive outsourced services and solutions for the deployment and maintenance of next-generation and legacy wireless and wireline telecommunication networks and infrastructure. Also today, NetworkNewsWire released a report on the company detailing how SGSI recently announced that it has obtained an additional $3.3 million in contracts (http://nnw.fm/1AN6f ). To view the full article, visit http://nnw.fm/eLbu0 .

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Tuesday's trading session at $0.026, off by 25.7143%, on 152,765 volume with 17 trades. The average volume for the last 3 months is 188,291 and the stock's 52-week low/high is $0.014999999/$0.800000011.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.